Full-Time

Clinical Development Manager

Clinical Development and Validation

Updated on 9/3/2026

Butterfly Network

Butterfly Network

201-500 employees

Handheld ultrasound device for point-of-care imaging

Compensation Overview

$185k/yr

+ Bonus + Equity

No H1B Sponsorship

New York, NY, USA + 1 more

More locations: Burlington, MA, USA

Hybrid

At least two days per week in the office; travel up to 50% required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Software Testing
Neural Networks

Get referred to Butterfly Network

See people who can refer or advise you

Requirements
  • A minimum of 3 years of research and development experience or equivalent.
  • A minimum of 5 years of experience utilizing ultrasound medical imaging and medical technologies in diverse clinical environments, with a firm understanding of product attributes that lead to positive user and patient outcomes.
  • Active ARDMS certification is required.
  • At least 5 years of experience in diagnostic ultrasound with point-of-care ultrasound market expertise is required.
  • Current RDMS, RVT, and/or RDCS registration is required.
  • Ability to understand both the clinical and business needs of the customer and Butterfly Network.
  • Ability to translate customer needs into clear product requirements for research and development.
  • Ability to think about the application of diagnostic ultrasound in non-traditional ways.
  • Ability and willingness to travel up to 50%.
Responsibilities
  • Assist with customer engagements, focus groups, user groups, advisory boards, and other market-related activities to collect, define, and validate commercial needs and requirements.
  • Work with clinical specialists, software, integration, and systems engineering teams to participate in validating design outputs.
  • Develop working knowledge of diagnostic and monitoring tools used by point-of-care physicians in their practice.
  • Identify and report clinical trends gathered through scientific congresses, customer seminars, and education events.
  • Define, document, and execute clinical validation tests, including maintaining traceability to requirements.
  • Create, maintain, and distribute plans and reports promptly to support product development timelines.
  • Participate in system life-cycle and software integration testing.
  • Participate in reviews and improvement of requirements, design documents, and overall processes.
  • Create and contribute to documentation including the Product Requirements Definition, Clinical Evaluation Report, Clinical Validation Plan, and Clinical Validation Report.
  • Carry out the requirements of Butterfly Network's quality procedures.
  • Provide clinical support and input cross-functionally to the design and development process as needed.
  • Provide product support to Commercial, Marketing, Clinical Applications, and other cross-functional teams.
  • Perform tasks supporting the role and its responsibilities.
Desired Qualifications
  • A bachelor's degree in Biomedical or Ultrasound.
  • Fluency in multiple languages, including spoken and written English.
  • Ability to work effectively in a team environment.

Butterfly Network makes medical imaging tools, focusing on point-of-care ultrasound (POCUS). Its main product is the Butterfly iQ, a handheld ultrasound device that uses a single probe to scan the whole body. The iQ connects to a software platform, storing images, supporting telehealth, and providing advanced imaging tools. The device is sold to doctors, nurses, and medical technicians in hospitals, clinics, and rural settings, with revenue from device sales, software subscriptions, and educational resources. What sets Butterfly Network apart is its single-probe, portable design that aims to simplify ultrasound workflows and make high-quality imaging more affordable and accessible, especially in underserved areas. The company’s goal is to improve diagnostic access and patient outcomes worldwide by delivering cost-effective, easy-to-use ultrasound technology that integrates hardware and software in one connected system.

Company Size

201-500

Company Stage

IPO

Headquarters

Burlington, Massachusetts

Founded

2011

Get referred to Butterfly Network

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 39% to $32.6 million; gross margin reached 71.4%.
  • Butterfly raised 2026 revenue guidance to $119 million-$123 million after Embedded surged 439%.
  • Brazil launch and first Home and Community Care rollout expand distribution in Q3-Q4 2026.

What critics are saying

  • Fujifilm Sonosite sued Butterfly in Delaware on March 9, 2026 over seven patents.
  • H1 2026 operating cash outflow hit $30.2 million despite $124.7 million cash.
  • GE HealthCare, Philips, and Clarius compress handheld pricing and threaten Butterfly’s hardware moat.

What makes Butterfly Network unique

  • Ultrasound-on-Chip keeps Butterfly the only true handheld whole-body probe, powering Embedded partners.
  • Merge Labs chose Butterfly as exclusive ultrasound-chip supplier in its 2026 brain-interface program.
  • More than 800 patents protect Butterfly’s platform against clone handheld ultrasound competitors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health, dental & vision insurance

Equity

401k

PTO

Flexible hybrid work

Parental leave

Home office stipend

Rewards & recognition program

LinkedIn Learning

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Sep 3rd, 2026
Sam Altman-backed Merge Labs selects Butterfly Network as exclusive ultrasound chip supplier for brain interfaces

Merge Labs, a brain-interface startup backed by OpenAI and Sam Altman, has selected Butterfly Network as its exclusive ultrasound-on-chip supplier under a multiyear agreement. The deal includes upfront payments, development milestones, purchase commitments, access fees, and potential royalties, though specific amounts were not disclosed. Butterfly's semiconductor-based ultrasound architecture makes the system programmable and easier to embed in new devices. The company retained rights to license its technology to other partners. Butterfly's second-quarter revenue increased 39% to $32.6 million, with gross margin expanding to 71.4%. Adjusted EBITDA loss narrowed 78% to $1.4 million. Management raised full-year revenue guidance to $119 million to $123 million. Thirty-three hedge funds held Butterfly Network in the second quarter, up from 26 in the first quarter.

Yahoo Finance
Aug 26th, 2026
Three AI small caps poised for growth as interest rate hikes plateau

Central banks signalling fewer interest rate hikes could support early-stage AI companies outside big tech. A new screener has identified 29 AI small-cap stocks positioned to benefit from the next wave of machine learning and automation. Butterfly Network, a medical imaging company, combines handheld ultrasound devices with AI-powered Compass software. The firm recently posted record quarterly revenue with strong gross margins. However, it remains unprofitable and trades at a high price-to-sales multiple, whilst experiencing significant insider selling. Pagaya Technologies operates an AI-driven loan decisioning platform serving banks, fintechs, and auto lenders. The platform assesses and prices consumer and small business credit in real time. The screener surfaced 26 additional companies with similar growth potential in AI-powered sectors.

Yahoo Finance
Aug 14th, 2026
Butterfly Network CEO sells $684K in shares after 629% stock surge

Joseph Devivo, president and CEO of Butterfly Network, sold 68,346 shares of Class A common stock on 10 August 2026, according to a SEC Form 4 filing. The transaction, valued at approximately $684,143, was executed through a Rule 10b5-1 trading plan adopted in December 2025. Following the sale, Devivo retains direct ownership of approximately 7.6 million shares, representing a market value of roughly $74 million. Butterfly Network shares closed at $9.37 on 11 August 2026, having achieved a 629% return over the preceding 12 months. The Burlington-based medical device company, which manufactures portable ultrasound imaging devices including the Butterfly iQ, reported trailing-twelve-month revenue of $112 million and a net loss of $75 million. The company maintains a market capitalisation of $2.3 billion.

Yahoo Finance
Jul 31st, 2026
Butterfly Network raises 2026 guidance to $123M as embedded revenue surges 439%

Butterfly Network raised its full-year 2026 revenue guidance to $119 million–$123 million, driven by growth in Point-of-Care Ultrasound, Home and Community Care, and Embedded partnerships. The company reported record gross margins of 71%, attributed to high-margin contributions from its Embedded segment. The Embedded business saw revenue increase 439%, primarily from the Midjourney partnership. Butterfly's enterprise software pipeline, Compass AI, has grown fivefold since last year. The company now serves 80% of US medical schools. International revenue fell 14% due to timing of large deals shifting to Q3. The company expects its first Home and Community Care commercial implementation on 1 October, with Q4 revenue anticipated. Butterfly plans to launch a next-generation probe in Q1 2027 and enter the ultrasound cart market in late 2027 with iQ Station.

Yahoo Finance
Jul 22nd, 2026
Butterfly Network founder Rothberg sells $20.7M in shares for estate planning

Jonathan Rothberg, founder and independent director of Butterfly Network, sold approximately 3.1 million Class B shares at $6.64 each, totalling $20.7 million, according to an SEC filing. The sale was conducted under a Rule 10b5-1 trading plan adopted in March 2026 for estate planning purposes. Following the transaction, Rothberg directly holds roughly 106,000 shares and indirectly controls about 19.6 million shares through various entities including family trusts. The sale occurred as Butterfly Network shares returned 263% over the preceding 12 months. Butterfly Network develops portable ultrasound imaging devices that connect to smartphones and tablets. The company has a market capitalisation of $1.8 billion, with trailing twelve-month revenue of $102.9 million and a net loss of $75.8 million.